Commercial Partnerships & Notable Stakeholders

Developing Global Relationships

Numerous business, research and funding relationships have achieved significant momentum. The Company is leveraging its expertise, knowledge and multiple opportunities into the mainstream investment community in order to accelerate the pace of activity towards commercialization.

Notable Current Stakeholders in SGN Nanopharma

  • Novavax Inc. (Nasdaq Listed, NVAX; Market Cap $2B)
  • Physician Investors (including notable ophthalmologists, Plastic surgeons – see Physician Advisory Board
  • Family Offices

Commercial Partnerships

  • Sunways (India), Private Ltd – Our lead formulation, Nano-cyclosporine for dry eye, “NanoTearsTM”, was launched by our marketing partner, Sunways in India in April, 2015. Sunways, incorporated in 1951 and based in Mumbai, is a medium sized pharma company that manufactures and markets a wide range of formulations in ophthalmology and ENT.
  • Wintac Limited – is one of our manufacturing partners. Wintac focuses in the manufacture of small volume & large volume parenterals as well as sterile ophthalmic preparations. Their state-of-the-art manufacturing facility is approved by several international regulatory agencies including the US FDA, ANSM (French Regulatory), TGA (Australian Regulatory), Health Canada (Certification) and Pharmacy & Poison Board, Kenya.
  • Syncom Healthcare Ltd – is our manufacturing partner, with whom we have a loan license to manufacture our pharmaceutical formulations. The company is located in Northern India and is a state-of-art manufacturing facility with an area of 4,397 Sq. meter and accredited with WHO cGMP Certification with a capacity to make variety of dosage forms for emerging markets.

Ongoing Late-Stage Partnership Discussions in India

  • Several ongoing and in some instances, late-stage.

Get News Updates